Karyopharm Therapeutics Inc Stock Price, News & Analysis

Karyopharm Therapeutics (Nasdaq: KPTI) has appointed Lori Macomber as Executive Vice President, Chief Financial Officer and Treasurer, effective January 3, 2025. Macomber brings over 20 years of experience in life science companies' financial management, most recently serving as CFO at Legend Biotech

As part of her appointment, Macomber will receive inducement awards including a non-statutory stock option to purchase 650,000 shares and 160,000 restricted stock units (RSUs). The stock options will vest over four years, with 25% vesting after the first year and 1/48th monthly thereafter. The RSUs will vest over three years, with 33 1/3% vesting annually. Both awards include immediate vesting provisions in case of a change in control event followed by qualifying termination.

Karyopharm Therapeutics (Nasdaq: KPTI) has appointed Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications. Strong joins from Argot Partners, where he served as Managing Director advising biopharmaceutical companies. His previous experience includes roles as investor relations lead at Tenet Healthcare, CFO of Tenet's Massachusetts Market, and equity research positions at Lehman Brothers and Barclays.

The company emphasizes Strong's experience will be valuable as they approach important milestones in 2025, particularly in advancing their late-stage pipeline and building on their multiple myeloma foundation. Strong holds an MBA from Harvard Business School and a B.S. in Finance from Rutgers University.

Karyopharm Therapeutics (Nasdaq: KPTI) announced it is in discussions with the FDA regarding the evolving treatment landscape in endometrial cancer and potential implications for their Phase 3 XPORT-EC-042 trial. Due to these ongoing discussions, the company will not address its endometrial cancer program at the Piper Sandler Healthcare Conference. An update will be provided after the FDA discussion concludes.

Karyopharm Therapeutics has announced the granting of 4,800 restricted stock units (RSUs) to two newly-hired employees as of November 30, 2024. The RSUs were granted under the company's 2022 Inducement Stock Incentive Plan, following Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over three years, with 33 1/3% vesting annually. Full vesting is subject to continued employment, with immediate vesting possible in case of qualifying termination following a change in control event.

Karyopharm Therapeutics (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on novel cancer therapies, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The company's senior management team will engage in a fireside chat on Tuesday, December 3 at 11:30 a.m. ET in New York.

The event will be accessible via live webcast in the Investor section of Karyopharm's website under 'Events & Presentations,' with replay availability after the event.

Karyopharm Therapeutics (Nasdaq: KPTI) has appointed Kristin Abate as Vice President, Chief Accounting Officer, and Assistant Treasurer, effective November 20, 2024. Abate, who has been serving as interim principal financial officer and interim principal accounting officer since November 6, 2024, will continue as interim principal financial officer. With over 15 years of finance experience, she joined Karyopharm in July 2019 and previously worked at PricewaterhouseCoopers LLP from 2007 to 2019. She holds a B.S. in Business Administration from Bryant University and a Masters of Science in Accountancy from Boston College.

Karyopharm Therapeutics (Nasdaq: KPTI) announced its upcoming presentations at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, December 7-10, 2024. The presentations will showcase data on selinexor across multiple studies.

The presentations include two posters: one examining the efficacy and safety of selinexor, pomalidomide, and dexamethasone (SPd) for relapsed/refractory multiple myeloma, and another studying selinexor's effect on ruxolitinib refractory myelofibrosis. Additionally, their partner Antengene will present data comparing weekly selinexor, bortezomib, and dexamethasone versus twice-weekly bortezomib and dexamethasone in Chinese patients with relapsed/refractory multiple myeloma.

Karyopharm Therapeutics reported Q3 2024 financial results with total revenue of $38.8 million, including U.S. XPOVIO net product revenue of $29.5 million. The company narrowed its full-year 2024 guidance, projecting total revenue of $145.0-155.0 million and U.S. XPOVIO net product revenue of $110.0-115.0 million. Following FDA alignment, the Phase 3 SENTRY trial in myelofibrosis will use Absolute Change in Total Symptom Score as a co-primary endpoint, with top-line data expected in 2H 2025. The company reported a net loss of $32.1 million for Q3 2024 and had cash reserves of $133.9 million as of September 30, 2024.

Karyopharm Therapeutics (Nasdaq: KPTI) has granted 10,500 restricted stock units (RSUs) to three newly-hired employees as of October 31, 2024. The RSUs were awarded under the company's 2022 Inducement Stock Incentive Plan and will vest over three years, with 33 1/3% vesting annually. The grants serve as employment inducements in compliance with Nasdaq Listing Rule 5635(c)(4). The RSUs include accelerated vesting provisions in case of employment termination following a change in control event.